Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III
Biogen and UCB detailed Phase III PHOENYCS GO trial results for dapirolizumab pegol, showing a 49.5% response rate vs. 34.6% with standard care, significant in lupus. DZP hit key secondary endpoints, improved disease activity scores, and corticosteroid tapering, with a well-tolerated side effect profile. A second Phase III trial is planned.
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Phase 3 PHOENYCS GO study results show dapirolizumab pegol significantly reduces SLE disease activity, with a favorable safety profile.
Related Clinical Trials:
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology
Dapirolizumab pegol (DZP) met primary endpoint in Phase 3 PHOENYCS GO study, showing significant improvement in SLE disease activity. DZP plus standard of care (SOC) resulted in 50% fewer severe flares and a favorable safety profile compared to SOC alone.
Related Clinical Trials:
EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
EU approves 2 aflibercept biosimilars; Biosimilars Canada launches #SaveBigWithBiosimilars campaign; Celltrion presents positive data for denosumab and tocilizumab biosimilars.
New Postmarketing Registry to Evaluate Real-World Safety and Patient Experience With Omaveloxolone
At the 2024 ICAR, the SKYCLARYS PASS registry (NCT06623890) was presented to collect long-term safety and patient experience data on omaveloxolone, an FDA-approved treatment for Friedreich ataxia. The registry will follow 300 omaveloxolone-naïve patients for up to 5 years, focusing on potential risks like drug-induced liver injury and congestive heart failure, with annual reports to the European Medicines Agency and FDA interim analyses. The study also explores health-related quality of life and healthcare resource utilization.
Biogen/UCB's Lupus Drug Shows Consistent Efficacy Across Endpoints, Over Time
Biogen/UCB’s lupus drug, dapirolizumab pegol, demonstrated consistent efficacy across all endpoints in its first Phase III study, with meaningful improvements over placebo over time. A second Phase III trial is planned for this year.
Biogen, UCB detail response rates in Phase III lupus win
The article discusses the importance of enabling JavaScript for optimal app performance.
Biosimilar referencing aflibercept from Samsung Bioepis approved by European Commission
The EC approved OPUVIZ 40 mg/mL, a biosimilar referencing Eylea, for treating neovascular AMD, macular edema secondary to RVO, DME, and myopic CNV. Developed by Samsung Bioepis, OPUVIZ aims to expand access to vital biologic therapies for retinal disorder patients in Europe.
Breakthrough drug 'step closer to saving lives' following MND Association campaign
NICE reconsidered its decision for Tofersen, a drug that slows MND progression in SOD1 patients, following the MND Association's Prescribe Life campaign. The HST route now gives Tofersen the best chance of approval, offering hope to those affected.
© Copyright 2024. All Rights Reserved by MedPath